How does Myomo's performance and valuation compare to peers such as SynTouch or Neuronetics?

Short answer:

The short‑form announcement you shared about Myomo’s upcoming Q2‑2025 earnings release does not contain any financial metrics (revenues, earnings, cash‑flow, market‑cap, valuation multiples, etc.) that would allow a direct, data‑driven comparison of Myomo’s performance or valuation with peer companies such as SynTouch or Neuronetics.

Below is a structured guide on how you can make that comparison once the necessary data is in hand, along with a brief contextual note on the three companies and the typical metrics you’d examine.

1. Why the current news can’t answer the question directly

Because none of those quantitative pieces are present in the press release, any comparison would be speculative and could be misleading.

2. Framework for a “peer‑comparison” once data is available

A. Identify the relevant peer group

Because the business models differ (exoskeletons vs. haptic sensors vs. neuro‑stimulation), you should compare both financial metrics and the underlying market dynamics (e.g., TAM, reimbursement environment, regulatory pipeline).

B. Key financial metrics to collect (most recent quarterly / annual)

C. Valuation multiples (most common for high‑growth med‑tech)

D. Operational / strategic metrics (to contextualize the numbers)

3. How to actually perform the comparison

1. Collect the latest quarterly reports (10‑Q, 20‑F, earnings press releases) for each company.

   • Myomo: Expect the Q2‑2025 numbers on August 11, 2025.
     
   • SynTouch: Look for the most recent quarter (e.g., Q2‑2025 or Q4‑2024, depending on filing schedule).
     
   • Neuronetics: Typically reports quarterly; the most recent 10‑Q should be available in early‑Q2‑2025 or Q1‑2025.
     

2. Extract the financial figures listed above. For private companies (like SynTouch) that may not be publicly listed, you’ll need to rely on private‑company databases (e.g., PitchBook, S&P Capital IQ) or press releases that disclose revenue ranges.

3. Calculate the valuation multiples using the most recent share price (for public companies) and the market‑cap (or Enterprise Value = market‑cap + debt – cash).

4. Benchmark:

   • Revenue growth: Compare YoY % growth to see who is expanding fastest.
     
   • Profitability: Check who has positive EBITDA, net income, or at least an improving operating margin.
     
   • Valuation: Compare P/S or EV/Revenue to understand how the market values each revenue dollar.
     
   • R&D intensity: A higher R&D % may signal a more advanced product pipeline but also higher cash burn.
     

5. Interpret the results:

   • If Myomo’s P/S is significantly higher than SynTouch’s, the market may be pricing in a larger addressable market (e.g., the U.S. exoskeleton market is projected to reach > $8 billion by 2030).
     
   • If Neuronetics has a higher P/E (if profitable), it may reflect higher profitability or a more mature product (e.g., FDA‑approved TMS devices).
     
   • If Myomo’s gross margin is lower, that could reflect higher component costs for exoskeletons; however, a rising margin trend would be a positive signal.
     

4. Example (illustrative, not actual data)

The above table is only a *template*. Replace it with actual numbers once the Q2‑2025 results are released and the latest SynTouch / Neuronetics data are obtained.

Interpretation (illustrative):

- If Myomo’s P/S ends up at 8×, the market is valuing it higher than both peers, implying investors expect a faster ramp‑up of device sales and a larger TAM.

- If EV/EBITDA for Myomo is 25× (higher than Neuronetics' 22×), investors may be pricing in stronger growth or better margins.

- Conversely, a lower cash position (e.g., $20 M) would signal the need for additional financing, possibly diluting shareholders if the company raises equity.

5. What to watch in Myomo’s upcoming release (August 11, 2025)

1. Revenue trend: Compare Q2‑2025 vs. Q2‑2024 and Q1‑2025 to gauge momentum.
   
2. Gross & Operating margins: Indicate cost‑structure improvement as scale rises.
   
3. R&D spend: A higher R&D share may signal a new device or an expanded indication (e.g., stroke, spinal‑cord injury).
   
4. Cash position: Critical for a hardware‑heavy company that may need additional financing for production ramp‑up.
   
5. Guidance: Look for 2025 full‑year guidance; compare it with the forward‑looking valuations of peers (e.g., “We expect FY‑2025 revenue of $XX‑$XX M, implying a 30 % YoY growth – higher than the 20 % growth forecasted for SynTouch and 12 % for Neuronetics”).
   

6. Bottom‑line answer to your question

Based on the information you provided (a brief announcement of Myomo’s upcoming earnings call), there is insufficient data to compare Myomo’s performance or valuation to those of SynTouch or Neuronetics.

To perform a rigorous comparison you’ll need:

• Myomo’s Q2‑2025 financial results (revenue, earnings, cash, debt, R&D spend, etc.).
  
• Comparable metrics for SynTouch (if publicly listed or from a reliable private‑company source).
  
• Neuronetics’ most recent quarterly numbers (publicly available via SEC filings).
  

Once you have those data points, you can apply the framework above (revenue growth, margins, cash‑burn, and valuation multiples) to produce a concrete, data‑driven comparison.

If you would like, I can retrieve the latest 10‑Q filings for Neuronetics, summarize SynTouch’s latest disclosed financials (if available), and then build a side‑by‑side table once Myomo’s results are released. Let me know when you have the Q2‑2025 numbers or if you would like me to start pulling the other companies’ data now.